Nonproliferative retinopathy - Biotech, Pharma and Life Science Channel

01:57 EDT 20th September 2014 | BioPortfolio

PubMed Articles [289 Associated PubMed Articles listed on BioPortfolio]

Spectral-Domain and Swept-Source OCT Imaging of Asteroid Hyalosis: A Case Report.

A 72-year-old man with diabetes was referred to the retina clinic for diabetic retinopathy. Detailed funduscopic examination of the left eye was limited by prominent asteroid hyalosis. Spectral-domain...

Detection of Serum Antibodies Cross-Reacting with Mycobacterium avium Subspecies paratuberculosis and Beta-Cell Antigen Zinc Transporter 8 Homologous Peptides in Patients with High-Risk Proliferative Diabetic Retinopathy.

MAP3865c, a Mycobacterium avium subspecies paratuberculosis (MAP) cell membrane protein, has a relevant sequence homology with zinc transporter 8 (ZnT8), a beta-cell membrane protein involved in Zn++ ...

Raman spectroscopy for a rapid diagnosis of sickle cell disease in human blood samples: a preliminary study.

Raman spectroscopy has been proposed as a tool for diagnosis of human blood diseases aiming a quick and accurate diagnosis. Sickle cell disease arises in infancy and causes a severe anemia; thus, an e...

The Ocular Benefits of Estrogen Replacement Therapy: A Population-Based Study in Postmenopausal Korean Women.

To elucidate the prevalence of cataract, glaucoma, pterygia, and diabetic retinopathy among Korean postmenopausal women with or without estrogen replacement therapy (ERT).

DBA/2J Mice Are Susceptible to Diabetic Nephropathy and Diabetic Exacerbation of IOP Elevation.

Some pathological manifestations of diabetes in the eye include retinopathy, cataracts and elevated intraocular pressure (IOP). Loss of retinal ganglion cells (RGCs) in non-proliferative stages of dia...

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.

The role of statins in the development of microvascular disease in patients with diabetes is unknown. We tested the hypothesis that statin use increases the risk of diabetic retinopathy, diabetic neur...

The Cross-Sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.

Longitudinal evidence linking diabetic retinopathy with changes in brain structure and cognition is sparse. We used data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to de...

Activation of the Endothelin System Mediates Pathological Angiogenesis during Ischemic Retinopathy.

Retinopathy of prematurity adversely affects premature infants because of oxygen-induced damage of the immature retinal vasculature, resulting in pathological neovascularization (NV). Our pilot studie...

Erythrocyte Phospholipid and Polyunsaturated Fatty Acid Composition in Diabetic Retinopathy.

Long chain polyunsaturated fatty acids (LCPUFAs) including docosahexaenoic acid and arachidonic acid are suspected to play a key role in the pathogenesis of diabetes. LCPUFAs are known to be preferent...

Scutellarin Inhibits High Glucose-induced and Hypoxia-mimetic Agent-induced Angiogenic Effects in Human Retinal Endothelial Cells Through Reactive Oxygen Species/Hypoxia-inducible Factor-1α/Vascular Endothelial Growth Factor Pathway.

: Scutellarin inhibits hypoxia-induced and moderately high glucose-induced proliferation and vascular endothelial growth factor (VEGF) expression in human retinal endothelial cells (HRECs); thus, it c...

News Articles [119 Associated News Articles listed on BioPortfolio]

Call for Better Diabetic Retinopathy Screening in Pregnancy

Although guidelines for pregnant diabetic women recommend at least 2 retinal eye exams in separate trimesters, many women do not have these exams, so new or worsening retinopathy is missed. Meds...

EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023

Recently added to the BioPortfolio report store, EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023 is a new report from GlobalData published on 2014-09-09. This 55-page report is...

Regeneron drug wins FDA breakthrough status for diabetic retinopathy

Regeneron Pharmaceuticals' Eylea has received breakthrough therapy status from the FDA as a treatment for diabetic retinopath -More- 

Regeneron Eylea wins 'breakthrough' in DME diabetic retinopathy

Shares of Regeneron gained 3% on 16 September, before closing at $355.47, up $2.73, or 2.73%.

EYLEA Receives FDA Breakthrough Therapy Designation

Regeneron Pharmaceuticals' injection for diabetic retinopathy in patients with diabetic macular edema received FDA breakthrough therapy designation on Sept. 16, 2014.

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

US biotech firm Regeneron Pharmaceuticals says that the US Food and Drug Administration has granted Eylea (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinop...

EYLEA Injection Receives FDA Breakthrough Therapy Designation

Regeneron Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic reti...

Tuesday's most followed in U.S. including Allergan, Humana, Regeneron, Siga Technologies, Dick’s Sporting Goods, Sears Holdings, Hershey, PBF Logistics, Microsoft, PG&E

U.S. shares wavered as the Federal Reserve began a two-day policy meeting. The S&P 500 (INDEXSP:.INX) rose 0.3 percent at 11:33 a.m. in New York. The 30-company Dow Jones Industrial Average (INDEX...

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic reti...

A new therapeutic target may prevent blindness in premature babies at risk of retinopathy

Possibility of developing new, more selective drugs to control the abnormal growth of blood vessels and prevent blindness including retinopathy of prematurity, a disorder that may result in retinal de...

Events [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye di...

Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to de...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By...

NormOxys, Inc.

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen def...

Acucela

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the ...

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficia...

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (the STOP-ROP Multicenter Trial)

To test the efficacy, safety, and costs of providing supplemental oxygen in moderately severe retinopathy of prematurity (prethreshold ROP).

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

To determine the safety and efficacy of trans-scleral cryotherapy of the peripheral retina in certain low birth-weight infants with retinopathy of prematurity (ROP) for reducing blindness ...

Sorbinil Retinopathy Trial (SRT)

To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons wit...

Krypton-Argon Regression of Neovascularization Study (KARNS)

To evaluate whether red krypton laser treatment is as effective at causing regression of diabetic disc neovascularization as treatment with the blue-green argon laser, when both lasers are...

Early Treatment Diabetic Retinopathy Study (ETDRS)

To evaluate the effectiveness of both argon laser photocoagulation and aspirin therapy in delaying or preventing progression of early diabetic retinopathy to more severe stages of visual l...

Diabetic Retinopathy and Visual Function Study

The purpose of this study is to evaluate possible mechanisms of central visual loss in patients with diabetes mellitus. The visual loss of interest to be investigated is that associated w...

Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)

Patients enrolled in the original Early Treatment Diabetic Retinopathy Study at the Clinical Center at Johns Hopkins Wilmer Eye Institute will be invited for a follow-up visit at the Natio...

Blood Factors and Diabetic Retinopathy

This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy. Patients age 10 years and older with diabetes mellitus and diabeti...

Retinal Arteriolar Abnormalities and CV Mortality

To determine whether retinal arteriolar changes (generalized narrowing, focal narrowing and arterio-venous nicking) and retinopathy were associated with 10-year stroke-and ischemic heart ...

Medical and Biotech [MESH] Definitions

A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

Degenerative changes to the RETINA due to HYPERTENSION.

A drug used to reduce hemorrhage in diabetic retinopathy.

Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.

Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Nonproliferative retinopathy market research data and corporate reports here

Channels Quicklinks